Table 2.

Correlation of DNA methylation status with clinicopathological parameters in ccRCC tissue at cg18345635 (in TCGA cohort) and at 05_CpG_8.9 (in TuCP2)

cg18345635 (TCGA)05_CpG_8.9 (TuCP2)
Median signal methylation array (range)P-valueaMedian% DNA methylation (range)P valuea
Age0.0311 (rs = −0.13)0.1760 (rs = 0.18)
Sex0.00140.1079
 Male0 (−0.35–0.26)56 (20–90)
 Female0.06 (−0.25–0.3)64 (24–93)
Tumor size0.2409 (rs = −0.15)
T<0.00010.8890
 1/20.05 (−0.3–0.3)58 (25–93)
 3−0.04 (−0.35–0.25)63 (20–91)
N0.00180.0098
x/00.02 (−0.35–0.3)61.5 (20–93)
 1/2−0.16 (−0.23–0.03)47 (24–83)
M0.07110.0333
 00.03 (−0.35–0.3)63 (20–93)
 1−0.03 (−0.28–0.24)49 (24–83)
G<0.00010.0009
 10.1 (0.04–0.16)68.5 (45–93)
 20.06 (−0.24–0.3)60 (25–91)
 3/4−0.03 (−0.35–0.25)41 (20–65)
L0.0495
 059 (20–93)
 147 (37–49)
V0.9395
 058.5 (25–93)
 1/260.5 (20–91)
R0.3090
 059 (20–93)
 148 (37–80)
Tumor necrosis0.0180.0050
 Yes−0.01 (−0.35–0.25)47.5 (24–56)
 No0.04 (−0.3–0.3)63 (20–93)
Sarcomatoid differentiation0.0041
 Yes59.5 (24–93)
 No43 (20–49)
Recurrence0.400
 Yes51 (20–72)
 No59 (24–93)
Overall survivalb0.00010.0051
 Deceased−0.04 (−0.35–0.25)49.5 (20–72)
 Alive0.04 (−0.3–0.3)63 (24–93)

Abbreviations: G, grading; L, invasion into lymph vessels; M, distant metastasis; N, regional lymph nodes; T, primary tumor; R, resection status; V, invasion into veins.

  • aUnadjusted P values.

  • bOverall survival and cancer-specific survival is identical in the TuCP2 cohort.